NE
Nectar Lifescience Ltd (NECLIFE)
₹9.81
Mkt cap
₹200 Cr
P/E ratio
—
P/B
0.33
Div yield
0.00%
ROE
−31.30%
ROCE
0.05%
EPS (TTM)
—
Book value
₹29
52W range
9–22
Sector
Healthcare
Price history
Previous close
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations [1]
NSE NECLIFEBSE 532649
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsBearish
52-week range
−56.21% from high₹10
₹9+5.48% from low₹22
Current
₹9.81
Prev close
₹9.98
Day
−1.70%
Price performance
1D
−1.70%
1W
−7.97%
1M
−8.83%
3M
−4.66%
6M
−19.66%
1Y
−33.49%
YTD
−51.24%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 397.97 | 452.17 | 441.38 | 359.30 | 5.74 | 0.01 | 0.01 | 5.24 | 0.71 | 0.00 | 1.29 | 0.44 | 0.01 | |
| YoY Sales growth | +2.40% | +31.40% | +13.52% | -8.84% | -98.56% | -100.00% | -100.00% | -98.54% | -87.63% | -100.00% | +12,800.00% | -91.60% | -98.59% | |
| Expenses | 371.11 | 409.98 | 392.88 | 319.49 | 6.33 | 0.06 | 0.06 | 6.08 | 0.16 | 1.93 | 58.53 | 27.71 | 6.69 | |
| Operating Profit | 26.86 | 42.19 | 48.50 | 39.81 | -0.59 | -0.05 | -0.05 | -0.84 | 0.55 | -1.93 | -57.24 | -27.27 | -6.68 | |
| OPM % | 6.75% | 9.33% | 10.99% | 11.08% | -10.28% | -500.00% | -500.00% | -16.03% | 77.46% | -4,437.21% | -6,197.73% | -66,800.00% | ||
| Other Income | 10.61 | 0.48 | 1.47 | 0.55 | 6.52 | 8.08 | -129.80 | -62.23 | -176.28 | 35.46 | -24.42 | 3.24 | 13.22 | |
| Interest | 20.52 | 24.84 | 24.16 | 19.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.22 | 5.90 | 0.16 | 0.00 | |
| Depreciation | 15.31 | 15.37 | 14.70 | 15.46 | 0.45 | 0.07 | 0.30 | 0.53 | 0.11 | 0.06 | 0.08 | 0.11 | 0.11 | |
| Profit before tax | 1.64 | 2.46 | 11.11 | 4.92 | 5.48 | 7.96 | -130.15 | -63.60 | -175.84 | 3.25 | -87.64 | -24.30 | 6.43 | |
| Tax % | 38.41% | 36.18% | 94.69% | 39.63% | -2.19% | 1.51% | -0.05% | -0.58% | 0.09% | -339.08% | -22.50% | -36.63% | 57.70% | |
| Net Profit | 1.02 | 1.57 | 0.59 | 2.97 | 5.60 | 7.84 | -130.09 | -63.23 | -176.01 | 14.27 | -67.92 | -15.40 | 2.72 | |
| EPS in Rs | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.80 | -2.82 | -7.85 | 0.64 | -3.50 | -0.79 | 0.14 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +2.09% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 14 Aug '26◦ |
| Earnings day | +2.09% |
| +1 day | −2.18% |
| +5 days | −2.55% |
| +15 days | +9.73% |
| +30 days | −2.64% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.84%Promoter
Promoters51.84%
FIIs0.50%
DIIs0.00%0.01
Public43.74%0.16
Government3.92%0.17
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,867.50 | 36.42 | 4,48,076 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,080.00 | 86.07 | 2,94,139 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,691.20 | 82.19 | 1,78,438 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,220.00 | 89.52 | 1,19,949 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,192.00 | 26.24 | 1,18,902 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,377.90 | 41.11 | 1,15,092 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,394.50 | 36.28 | 1,12,660 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Nectar Lifesci. | ₹10.31 | — | 200 | 0.00% | 3 | +1,086.67% | 0 | −98.59% | 0.05% |
| Median: 160 Co. | ₹449.50 | 33.40 | 2,018 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts3
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Nov - Nectar Lifesciences Limited has informed about Copy of Newspaper PublicationResults For Quarter And Half Year Ended September 30, 2026. 14 NovBoard Meeting Intimation for Financial Result And Other Business Matters 6 Nov - Board meeting on November 14, 2026 to consider Q2 FY2026-27 unaudited financial results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - Please find attached herewith certificate as per caption regulationsMinutes Of 31St Annual General Meeting ("AGM") 5 Oct - 31st AGM minutes: FY26 financials adopted; Sanjiv Goyal reappointed; two independent directors reappointed; Dr. Gunmala Suri appointed.






